In a major development for global health, the Serum Institute of India (SII) has partnered with the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of a new vaccine against the Bundibugyo strain of Ebola virus. CEPI has committed up to $8.6 million to support the vaccine’s development and prepare it for clinical testing.
The vaccine candidate, known as ChAdOx1 Bundibugyo, is based on the same adenoviral vector technology used in the successful Oxford-AstraZeneca COVID-19 vaccine. Researchers believe this platform can help speed up vaccine development and improve preparedness against future Ebola outbreaks.
The collaboration comes at a crucial time as the Bundibugyo strain continues to cause outbreaks in parts of Central Africa, particularly in the Democratic Republic of Congo (DRC) and Uganda. Unlike the more common Zaire strain of Ebola, there are currently no approved vaccines or treatments specifically designed for the Bundibugyo variant.
Under the agreement, Oxford scientists will continue preclinical research and regulatory preparations, while the Serum Institute will manufacture vaccine doses for upcoming clinical trials. CEPI selected the Oxford-SII vaccine as one of the most promising candidates following a global review of Bundibugyo Ebola vaccine technologies.
Speaking about the partnership, Serum Institute CEO Adar Poonawalla emphasized the company’s commitment to leveraging its large-scale vaccine manufacturing capabilities to ensure rapid production and equitable access if the vaccine proves successful.
Health experts believe that developing vaccines before outbreaks become widespread is critical for preventing future epidemics. If successful, the new vaccine could play a significant role in protecting vulnerable populations and strengthening global preparedness against emerging infectious diseases.
The partnership between Oxford, Serum Institute, and CEPI highlights the importance of international collaboration in addressing public health threats and advancing life-saving vaccine research.
Conclusion
The development of the ChAdOx1 Bundibugyo Ebola vaccine marks an important step toward combating a deadly virus that currently lacks approved preventive treatments. With $8.6 million in funding from CEPI and the combined expertise of Oxford University and the Serum Institute of India, the project offers new hope in the fight against Ebola and future epidemic threats.
Recommended Products
